Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1896 1
1897 1
1940 1
1946 1
1947 2
1950 1
1951 2
1953 1
1954 4
1955 2
1956 1
1957 2
1958 1
1959 2
1960 1
1961 4
1962 3
1963 4
1964 5
1965 3
1966 2
1967 5
1968 7
1969 7
1970 4
1971 13
1972 10
1973 9
1974 16
1975 27
1976 34
1977 14
1978 14
1979 20
1980 15
1981 22
1982 47
1983 37
1984 37
1985 37
1986 61
1987 43
1988 47
1989 52
1990 70
1991 52
1992 68
1993 49
1994 46
1995 47
1996 54
1997 60
1998 71
1999 81
2000 122
2001 131
2002 134
2003 158
2004 201
2005 196
2006 207
2007 257
2008 271
2009 291
2010 332
2011 330
2012 417
2013 452
2014 672
2015 721
2016 821
2017 840
2018 995
2019 1221
2020 1414
2021 1555
2022 1778
2023 1481
2024 1352
2025 726

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,107 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: motagizadeh
Page 1
Voclosporin.
[No authors listed] [No authors listed] 2023 Dec 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Dec 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 34699156 Free Books & Documents. Review.
Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.
Facon T, Moreau P, Baker R, Min CK, Leleu X, Mohty M, Karlin L, Armstrong NM, Tekle C, Schwab S, Risse ML, Martin T. Facon T, et al. Haematologica. 2024 Feb 1;109(2):604-616. doi: 10.3324/haematol.2023.283073. Haematologica. 2024. PMID: 37584290 Free PMC article. Clinical Trial.
This IKEMA subgroup analysis examined efficacy and safety of Isa-Kd versus Kd in patients who experienced early (n=61 [Isa-Kd], n=46 [Kd]) vs. late relapse (n=104 [Isa-Kd], n=72 [Kd]). ...However, the numbers of deaths were low and treatment exposure was sign …
This IKEMA subgroup analysis examined efficacy and safety of Isa-Kd versus Kd in patients who experienced early (n=61 [Isa-Kd] …
ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
[No authors listed] [No authors listed] Drugs R D. 2007;8(2):103-12. doi: 10.2165/00126839-200708020-00005. Drugs R D. 2007. PMID: 17324008 Review.
Under the terms of the agreement, Lonza will manufacture sufficient quantities of trans-ISA 247 in a GMP environment for use in the company's upcoming clinical trials. Isotechnika completed the phase III SPIRIT trial of ISA 247 for psoriasis in Canada. ...Half of th …
Under the terms of the agreement, Lonza will manufacture sufficient quantities of trans-ISA 247 in a GMP environment for use in the c …
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial.
Manier S, Dimopoulos MA, Leleu XP, Moreau P, Cavo M, Goldschmidt H, Orlowski RZ, Tron M, Tekle C, Brégeault MF, Shafer AT, Beksac M, Facon T. Manier S, et al. Haematologica. 2025 Mar 20. doi: 10.3324/haematol.2024.287200. Online ahead of print. Haematologica. 2025. PMID: 40109195 Free article.
All patients received standard VRd/Rd dosing; Isa-VRd patients received intravenous Isa (cycle 1, 10 mg/kg QW; cycles 2-17, Q2W; subsequent cycles, Q4W). ...Using this scoring, 26.7% of patients were frail (26.0% Isa-VRd; 27.6% VRd), and 72.0% non-frail (72.8 …
All patients received standard VRd/Rd dosing; Isa-VRd patients received intravenous Isa (cycle 1, 10 mg/kg QW; cycles 2-17, Q2 …
Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.
Banerjee R, Lo M, Martin TG 3rd. Banerjee R, et al. Future Oncol. 2021 Dec;17(35):4849-4860. doi: 10.2217/fon-2021-0778. Epub 2021 Sep 23. Future Oncol. 2021. PMID: 34553603 Review.
In this review we discuss the rationale and clinical trial experience to date with Isa-Kd. Although final IKEMA results are pending, Isa-Kd has emerged as an effective and tolerable therapy for patients with relapsed multiple myeloma. ...In this review, we discuss p …
In this review we discuss the rationale and clinical trial experience to date with Isa-Kd. Although final IKEMA results are pending, …
Population Pharmacokinetics of Isavuconazole in Adult: A Systematic Review.
Chen N, Wang X, Li Y, Yang P, Huang M, Lu X. Chen N, et al. Infect Drug Resist. 2023 Dec 8;16:7559-7568. doi: 10.2147/IDR.S434622. eCollection 2023. Infect Drug Resist. 2023. PMID: 38089964 Free PMC article. Review.
In recent years, population pharmacokinetic studies of ISA have been reported continuously. This paper aims to summarize the characteristics of population pharmacokinetic models of ISA in adults, and provide theoretical basis for individualized administration of …
In recent years, population pharmacokinetic studies of ISA have been reported continuously. This paper aims to summarize the characte …
ISA API: An open platform for interoperable life science experimental metadata.
Johnson D, Batista D, Cochrane K, Davey RP, Etuk A, Gonzalez-Beltran A, Haug K, Izzo M, Larralde M, Lawson TN, Minotto A, Moreno P, Nainala VC, O'Donovan C, Pireddu L, Roger P, Shaw F, Steinbeck C, Weber RJM, Sansone SA, Rocca-Serra P. Johnson D, et al. Gigascience. 2021 Sep 16;10(9):giab060. doi: 10.1093/gigascience/giab060. Gigascience. 2021. PMID: 34528664 Free PMC article.
To make the ISA framework more accessible to machines and enable programmatic manipulation of experiment metadata, the JSON serialization ISA-JSON was developed. RESULTS: In this work, we present the ISA API, a Python library for the creation, editing, parsin …
To make the ISA framework more accessible to machines and enable programmatic manipulation of experiment metadata, the JSON serializa …
ISA implementation and uncertainty: a literature review and expert elicitation study.
van der Pas JW, Marchau VA, Walker WE, van Wee GP, Vlassenroot SH. van der Pas JW, et al. Accid Anal Prev. 2012 Sep;48:83-96. doi: 10.1016/j.aap.2010.11.021. Epub 2011 Jan 16. Accid Anal Prev. 2012. PMID: 22664671 Review.
Experts indicate that there are still too many uncertainties surrounding ISA implementation, and dealing with these uncertainties is essential for implementing ISA. ...We found that the long-term effects and the effects of large-scale implementation of ISA ar …
Experts indicate that there are still too many uncertainties surrounding ISA implementation, and dealing with these uncertainties is …
Isoalantolactone: a review on its pharmacological effects.
Yang G, Yang L, Xu F. Yang G, et al. Front Pharmacol. 2024 Sep 23;15:1453205. doi: 10.3389/fphar.2024.1453205. eCollection 2024. Front Pharmacol. 2024. PMID: 39376605 Free PMC article. Review.
The anticancer effects of ISA involve proliferation inhibition, ROS overproduction, apoptosis induction and cell cycle arrest. Through inhibiting NF-kappaB signaling, ISA exerts its anti-inflammatory effects which are involved in the neuroprotection of ISA. . …
The anticancer effects of ISA involve proliferation inhibition, ROS overproduction, apoptosis induction and cell cycle arrest. Throug …
Isavuconazole-tacrolimus drug-drug interactions in HSCT patients.
Fructuoso-González L, Najera-Perez MD, Manresa-Ramón N, Torrano-Belmonte P, Caracena-López S, Pacheco-López P. Fructuoso-González L, et al. J Antimicrob Chemother. 2023 Oct 3;78(10):2559-2562. doi: 10.1093/jac/dkad271. J Antimicrob Chemother. 2023. PMID: 37667501
OBJECTIVES: Because tacrolimus has a narrow therapeutic window and exhibits both intraindividual and interindividual variability, we attempted to establish the percentage of calcineurin inhibitor (CNI) dose reduction to prevent toxicity and ensure stem cell engraftment when using …
OBJECTIVES: Because tacrolimus has a narrow therapeutic window and exhibits both intraindividual and interindividual variability, we attempt …
15,107 results
You have reached the last available page of results. Please see the User Guide for more information.